Severe Combined Immunodeficiency (SCID)

Definition and clinical overview

Definition: A heterogeneous group of genetic disorders characterized by profound defects in T‑cell development and function with variable B‑cell and NK‑cell involvement, leading to severe susceptibility to infections and infantile‑onset failure to thrive.

Typical immune phenotype: Most classic forms have absent or very low T cells with variable B and NK cell counts depending on the genetic defect.

Incidence and presentation

Incidence: Approximately 1:58,000 live births depending on region and newborn screening coverage.

Presentation: Severe, recurrent infections in early infancy, including Pneumocystis jirovecii pneumonia, persistent thrush, chronic diarrhea, failure to thrive, and severe vaccine‑related complications where live vaccines were given.

Gastrointestinal manifestations

• Failure to thrive and chronic diarrhea are common presenting features due to infections, malabsorption, and immune dysregulation.
• Oropharyngeal and esophageal candidiasis, including recurrent oral thrush and candidal esophagitis.
• Hepatosplenomegaly is frequently observed; hepatic and pancreatic involvement can include infectious hepatitis, pancreatitis, and graft‑versus‑host–like pathology of the liver.
• Omenn syndrome, an SCID variant, presents with erythroderma, lymphadenopathy, eosinophilia, and severe enteropathy.
• Autoimmune GI disease such as enteropathy and other autoimmune manifestations including glomerulonephritis and hemolytic anemia may occur.

Genetic variants and VEOIBD

Monogenic defects that cause atypical or leaky SCID can present primarily with very early‑onset inflammatory bowel disease (VEOIBD) before age 6; genes implicated include DCLRE1C, ZAP70, RAG2, IL2RG, LIG4, ADA, CD3G, and TTC7A, among others.

Management and definitive therapy

• Urgency: SCID is life‑threatening and typically fatal within the first years of life if untreated.
• Definitive therapy: Allogeneic hematopoietic stem cell transplantation (HSCT) is the standard curative therapy; outcomes are best when performed early, with highest survival when transplant occurs within the first 3½ months of life.
• Gene therapy: Advances in gene therapy provide curative options for selected genetic subtypes and are increasingly available.

Pretransplant principles and supportive care

• Isolation and infection prevention: Protective isolation and strict infection control to minimize pathogen exposure prior to definitive therapy.
• Prophylaxis: Pneumocystis jirovecii prophylaxis and targeted antimicrobial prophylaxis as indicated.
• Immunoglobulin replacement: Consider IVIG or subcutaneous replacement to reduce bacterial infections and support humoral immunity when indicated.
• Vaccination: Avoid live vaccines; administer inactivated vaccines only per immunology guidance.
• Nutrition: Optimize nutrition aggressively; enteral support with nasogastric or gastrostomy feeds is commonly required, and hydrolyzed formulas are often better tolerated.

Prognosis and follow-up

Early diagnosis—often via newborn screening—and prompt referral for HSCT or gene therapy have markedly improved outcomes; long‑term follow‑up is required to monitor growth, immune reconstitution, infectious complications, and late effects of curative therapy.

Clinical pearls